Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28604063 | 0.99 | PDE4B (0.44) | PDE4BTDO2DHFRCTSANUDT1 | |
| SCHEMBL16045314 | 0.88 | PDE4B (0.43) | PDE4BTDO2DHFRCTSANUDT1 | |
| Bromide SCHEMBL16044408 | 0.86 | PDE4B (0.43) | PDE4BTDO2DHFRCTSANUDT1 | |
| SCHEMBL28045842 | 0.85 | PDE4B (0.42) | PDE4BTDO2DHFRCTSANUDT1 | |
| SCHEMBL16114250 | 0.85 | PDE4B (0.42) | PDE4BTDO2DHFRCTSANUDT1 | |
| SCHEMBL16044201 | 0.83 | PDE4B (0.41) | PDE4BTDO2DHFRCTSANUDT1 | |
| SCHEMBL16075879 | 0.83 | PDE4B (0.41) | PDE4BTDO2DHFRCTSANUDT1 | |
| SCHEMBL16075838 | 0.83 | PDE4B (0.45) | PDE4BTDO2DHFRNUDT1HCRTR1 | |
| SCHEMBL16044727 | 0.83 | DHFR (0.45) | PDE4BTDO2DHFRNUDT1ADORA1 | |
| SCHEMBL16045080 | 0.82 | P2RX7 (0.44) | PDE4BKCNA5P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-06 | — | — | US | disclosed |
| EP-3345902-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart NeuroScience (Cayman) Ltd (KY) | 2018-07-11 | — | — | EP | disclosed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | disclosed |
| US-9573937-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-02-21 | — | — | US | disclosed |
| EP-2970212-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC | 2016-01-14 | — | — | US | disclosed |
| CN-105143207-A | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC | 2015-12-09 | — | — | CN | disclosed |
| US-20150329500-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-11-19 | — | — | US | disclosed |
| US-9120770-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-09-01 | — | — | US | disclosed |
| US-9040692-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-05-26 | — | — | US | disclosed |
| US-20140315913-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| WO-2014158998-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2471/4885DHFR 865/4885 |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2471/4885DHFR 865/4885 |
| US-20150329500-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2775/4885DHFR 1054/4885 |
| US-20140315913-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2775/4885DHFR 1054/4885 |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2775/4885DHFR 1054/4885 |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2472/4885DHFR 874/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2471/4885DHFR 865/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | PDE4B 2/4885TDO2 2472/4885DHFR 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.